Ryder System is viewed as a buy due to signs of trucking industry recovery, including better utilization rates and higher used truck prices in Q3. The company’s shift to asset-light, contract-driven revenue is expected to improve earnings quality and justify a premium valuation. The analyst targets $290 per share based on 2027 earnings estimates but suggests buying around $270 after a recent price jump. Risks include potential downturns affecting truck prices and rental demand, though contract revenue offers stability.
Ryder System is noted here with no direct Pluang data, so for readers following the Industrials sector, here is Pluang's market snapshot as of Oct 29, 2026 20:41 WIB: Out of 135 priced Industrials stocks, 92 advanced and 43 declined. Leading gainers include APG at USD 43.04 (+4.02%), GFL at USD 45.14 (+3.56%), and SARO at USD 22.99 (+3.51%), with typical hold times on Pluang ranging from 11 to 20 days.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
